PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31123968-3 2019 Increased COX-2 protein expression and PGE2 synthesis by LPS (1 mug/ml) were significantly and synergistically attenuated by cotreatment with 3 muM cilostazol and 30 muM celecoxib, whereas monotherapy with either cilostazol or celecoxib showed little effects. Celecoxib 170-179 latexin Homo sapiens 166-169 32183576-4 2020 Compounds 4a and 13 potently inhibited TNF-alpha (IC50 values: 2.01 and 6.72 muM, respectively) compared with celecoxib (IC50=6.44 muM). Celecoxib 110-119 latexin Homo sapiens 131-134 31123968-4 2019 IL-10 mRNA levels in LPS-treated RASFs were moderately increased by pretreating cilostazol (1-10 muM) or celecoxib (10-50 muM) monotherapy, but 3 muM of cilostazol add-on for 30 muM celecoxib treatment synergistically increased IL-10 mRNA levels and IL-10 release to culture media. Celecoxib 105-114 latexin Homo sapiens 122-125 31123968-3 2019 Increased COX-2 protein expression and PGE2 synthesis by LPS (1 mug/ml) were significantly and synergistically attenuated by cotreatment with 3 muM cilostazol and 30 muM celecoxib, whereas monotherapy with either cilostazol or celecoxib showed little effects. Celecoxib 227-236 latexin Homo sapiens 144-147 31123968-4 2019 IL-10 mRNA levels in LPS-treated RASFs were moderately increased by pretreating cilostazol (1-10 muM) or celecoxib (10-50 muM) monotherapy, but 3 muM of cilostazol add-on for 30 muM celecoxib treatment synergistically increased IL-10 mRNA levels and IL-10 release to culture media. Celecoxib 105-114 latexin Homo sapiens 122-125 30219715-2 2018 In recombinant CYP2D6, celecoxib hydroxylation showed atypical substrate inhibition kinetics with apparent Km, Ki, and Vmax of 67.2 muM, 12.6 muM, and 1.33 muM/min, respectively. Celecoxib 23-32 latexin Homo sapiens 132-135 31123968-4 2019 IL-10 mRNA levels in LPS-treated RASFs were moderately increased by pretreating cilostazol (1-10 muM) or celecoxib (10-50 muM) monotherapy, but 3 muM of cilostazol add-on for 30 muM celecoxib treatment synergistically increased IL-10 mRNA levels and IL-10 release to culture media. Celecoxib 105-114 latexin Homo sapiens 122-125 30219715-2 2018 In recombinant CYP2D6, celecoxib hydroxylation showed atypical substrate inhibition kinetics with apparent Km, Ki, and Vmax of 67.2 muM, 12.6 muM, and 1.33 muM/min, respectively. Celecoxib 23-32 latexin Homo sapiens 142-145 30219715-2 2018 In recombinant CYP2D6, celecoxib hydroxylation showed atypical substrate inhibition kinetics with apparent Km, Ki, and Vmax of 67.2 muM, 12.6 muM, and 1.33 muM/min, respectively. Celecoxib 23-32 latexin Homo sapiens 142-145 28038322-6 2017 Most of synthesized compounds were relatively more potent to celecoxib (0.78 muM), diclofenac (2.94 muM) and indomethacin (7.24 muM). Celecoxib 61-70 latexin Homo sapiens 77-80 28552400-5 2017 Celecoxib was shown to inhibit recombinant SULT1A1-catalyzed sulfonation of 10nM estrone and 4muM p-nitrophenol with IC50 values of 2.6 and 2.1muM, respectively, but did not inhibit SULT1E1-catalyzed estrone sulfonation. Celecoxib 0-9 latexin Homo sapiens 94-97 26637851-4 2015 At 48-h treatment, the glioma cells maintained 60% viability in the presence of celecoxib or LLW-3-6 at the maximum concentration tested (40 muM). Celecoxib 80-89 latexin Homo sapiens 141-144 27221835-5 2016 Celecoxib showed strong cytotoxic effects and induced apoptosis with an IC50 value of 40 muM. Celecoxib 0-9 latexin Homo sapiens 89-92 24972620-4 2014 Celecoxib at concentrations of 10-50 muM induced a [Ca(2+)]i rise in a concentration-dependent manner. Celecoxib 0-9 latexin Homo sapiens 37-40 25960318-4 2015 Low muM concentrations of celecoxib strikingly enhanced the formation of the 17-sulfates of 6-dehydroestradiol (6D-E2), 17beta-dihydroequilenin (17beta-Eqn), 17beta-dihydroequilin (17beta-Eq), and 9-dehydroestradiol (9D-E2) as well as the overall rate of sulfonation. Celecoxib 26-35 latexin Homo sapiens 4-7 26393789-8 2015 Celecoxib (65 muM) effectively inhibited cell proliferation under hypoxic conditions. Celecoxib 0-9 latexin Homo sapiens 14-17 24972620-12 2014 Celecoxib (10-50 muM) also induced apoptosis. Celecoxib 0-9 latexin Homo sapiens 17-20 23603366-6 2013 Celecoxib (10 muM) inhibits COX-1 mediated PGD2, and nitric oxide synthase (NOS) mediated NO in human OA-affected cartilage. Celecoxib 0-9 latexin Homo sapiens 14-17 25066075-4 2014 Cell culture assays performed in PC12, SKN-AS and U373-MG cells demonstrate the antiproliferative affects of CXB, with EC50 values of 99.81 muM and 82.4 muM in U373-MG and SKN-AS cells. Celecoxib 109-112 latexin Homo sapiens 140-143 25066075-4 2014 Cell culture assays performed in PC12, SKN-AS and U373-MG cells demonstrate the antiproliferative affects of CXB, with EC50 values of 99.81 muM and 82.4 muM in U373-MG and SKN-AS cells. Celecoxib 109-112 latexin Homo sapiens 153-156 24252689-5 2013 Glioblastoma cell lines were sensitive to both drugs and a combination of 100 muM celecoxib and 240 muM fluvastatin was the most synergistic. Celecoxib 82-91 latexin Homo sapiens 78-81 23603366-7 2013 Furthermore, celecoxib (1 muM) counter balances (IL-1beta induced+PGD2 modulated) levels of NO and PGE2 in human OA-affected cartilage and chondrocytes to basal levels. Celecoxib 13-22 latexin Homo sapiens 26-29 23200247-3 2013 In comparison, the celecoxib-dansyl conjugate (25) showed a slightly lower COX-2 potency and selectivity (COX-2 IC(50)=1.1 muM; SI>90) than the conjugate 10, and it possesses a better fluorescence emission (lambda(em)=500 nm). Celecoxib 19-28 latexin Homo sapiens 123-126 23200247-4 2013 Ultimately, a celecoxib-rhodamine B conjugate (28) that exhibited moderate COX-2 potency and selectivity (COX-2 IC(50)=3.9 muM; SI>25) having the best fluorescence emission (lambda(em)=580 nm) emerged as the most promising biomarker for fluorescence imaging using a colon cancer cell line that over-expresses the COX-2 isozyme. Celecoxib 14-23 latexin Homo sapiens 123-126 24520457-10 2013 The media in each experimental well contained either1, 10 or 50 muM of celecoxib. Celecoxib 71-80 latexin Homo sapiens 64-67 21886896-3 2011 It was more selective than the reference drug celecoxib (COX-2 IC(50) = 0.060 muM; selectivity index = 405). Celecoxib 46-55 latexin Homo sapiens 78-81 16267630-9 2006 All of the aforementioned effects were substantially reduced by the selective COX-2 inhibitor celecoxib (1 muM) at a pharmacologically relevant, nonapoptotic concentration. Celecoxib 94-103 latexin Homo sapiens 107-110